Xtant Medical Holdings financials
$0.3591+0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.9M | $117.3M | $91.3M | $58.0M | $55.1M | $53.2M | $64.5M | $71.8M | $82.5M | $90.0M |
| Gross profit | $84.3M | $68.2M | $55.5M | $32.1M | $32.4M | $34.2M | $42.4M | $43.1M | $50.0M | $62.3M |
| Gross margin | 62.9% | 58.2% | 60.8% | 55.4% | 58.7% | 64.4% | 65.6% | 60.0% | 60.6% | 69.2% |
| Operating income | $7.3M | -$12.1M | -$10.2M | -$6.8M | -$4.0M | -$900.0K | -$2.4M | -$60.5M | -$37.9M | -$7.5M |
| Net income | $5.0M | -$16.4M | $660.0K | -$8.5M | -$4.8M | -$7.0M | -$8.2M | -$70.1M | -$52.4M | -$19.5M |
| Net margin | 3.7% | −14.0% | 0.7% | −14.6% | −8.8% | −13.2% | −12.7% | −97.6% | −63.5% | −21.7% |
| Diluted EPS | $0.03 | $-0.12 | $0.01 | $-0.09 | $-0.06 | $-0.25 | $-0.63 | $-5.97 | $-34.76 | $-18.46 |
| EBITDA | $12.5M | -$7.8M | -$7.0M | -$5.5M | -$2.6M | $1.2M | $724.0K | -$1.2M | -$5.4M | $1.1M |
| Operating cash flow | $12.5M | -$11.9M | -$9.5M | -$5.3M | $439.0K | -$731.0K | -$413.0K | $1.2M | -$543.0K | -$14.4M |
| Free cash flow | $10.2M | -$16.0M | -$11.0M | -$7.1M | -$1.7M | -$2.3M | -$1.3M | $588.0K | -$2.2M | -$20.2M |
| Diluted shares | 150.0M | 133.7M | 126.8M | 94.1M | 85.5M | 28.5M | 13.2M | 11.7M | 1.5M | 1.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.1M | $6.2M | $5.7M | $20.3M | $18.2M | $2.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $25.4M | $34.3M | $22.0M | $15.6M | $15.5M | $16.8M |
| Total assets | $94.1M | $93.8M | $92.6M | $60.2M | $54.7M | $41.5M |
| Total liabilities | $43.2M | $50.9M | $41.3M | $26.1M | $23.8M | $27.0M |
| Shareholders' equity | $51.0M | $43.0M | $51.3M | $34.2M | $30.9M | $14.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology